Current status of proteomics of esophageal carcinoma

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499–2509.
   PubMed Web of Science ®Google Scholar
• Lepage C, Rachet B, Jooste V, et al. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008;103(11):2694–2699.
   PubMed Web of Science ®Google Scholar
• Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142–146.
   PubMed Web of Science ®Google Scholar
• Merkow RP, Bilimoria KY, McCarter MD, et al. Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals. Ann Surg Oncol. 2012;19(2):357–364.
   PubMed Web of Science ®Google Scholar
• Bollschweiler E, Metzger R, Drebber U, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2009;20(2):231–238.
   PubMed Web of Science ®Google Scholar
• Ohashi S, Miyamoto S, Kikuchi O, et al. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology. 2015;149(7):1700–1715.
   PubMed Web of Science ®Google Scholar
• Shimada H, Takeda A, Arima M, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89(8):1677–1683.
   PubMed Web of Science ®Google Scholar
• Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185(6):538–543.
   PubMed Web of Science ®Google Scholar
• Kaklamanos IG, Walker GR, Ferry K, et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol. 2003;10(7):754–761.
   PubMed Web of Science ®Google Scholar
• Malthaner RA, Wong RK, Rumble RB, et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med. 2004;2:35.
   PubMed Web of Science ®Google Scholar
• Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004;53(7):925–930.
   PubMed Web of Science ®Google Scholar
• Greer SE, Goodney PP, Sutton JE, et al. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery. 2005;137(2):172–177.
   PubMed Web of Science ®Google Scholar
• Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8(3):226–234.
   PubMed Web of Science ®Google Scholar
• Xu XH, Peng XH, Yu P, et al. Neoadjuvant chemotherapy for resectable esophageal carcinoma: a meta-analysis of randomized clinical trials. Asian Pac J Cancer Prev. 2012;13(1):103–110.
   PubMedGoogle Scholar
• Nguyen NP, Krafft SP, Vinh-Hung V, et al. Feasibility of tomotherapy to reduce normal lung and cardiac toxicity for distal esophageal cancer compared to three-dimensional radiotherapy. Radiother Oncol. 2011;101(3):438–442.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.
   PubMed Web of Science ®Google Scholar
• Uemura N, Kondo T. Current advances in esophageal cancer proteomics. Biochim Biophys Acta. 2015;1854(6):687–695.
   PubMed Web of Science ®Google Scholar
• Gao H, Zheng Z, Mao Y, et al. Identification of tumor antigens that elicit a humoral immune response in the sera of Chinese esophageal squamous cell carcinoma patients by modified serological proteome analysis. Cancer Lett. 2014;344(1):54–61.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Nakanishi T, Miyamoto Y, et al. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett. 2008;263(2):280–290.
   PubMed Web of Science ®Google Scholar
• Liu WL, Zhang G, Wang JY, et al. Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2008;375(3):440–445.
   PubMed Web of Science ®Google Scholar
• Zhao J, Fan YX, Yang Y, et al. Identification of potential plasma biomarkers for esophageal squamous cell carcinoma by a proteomic method. Int J Clin Exp Pathol. 2015;8(2):1535–1544.
   PubMed Web of Science ®Google Scholar
• Fan N-J, Gao C-F, Wang X-L. Tubulin beta chain, filamin A alpha isoform 1, and cytochrome b-c1 complex subunit 1 as serological diagnostic biomarkers of esophageal squamous cell carcinoma: a proteomics study. OMICS. 2013;17(4):215–223.
   PubMed Web of Science ®Google Scholar
• Hou G, Lou X, Sun Y, et al. Biomarker discovery and verification of esophageal squamous cell carcinoma using integration of SWATH/MRM. J Proteome Res. 2015;14(9):3793–3803.
   PubMed Web of Science ®Google Scholar
• Zhang LY, Ying WT, Mao YS, et al. Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. World J Gastroenterol. 2003;9(4):650–654.
   PubMed Web of Science ®Google Scholar
• Zaidi AH, Gopalakrishnan V, Kasi PM, et al. Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma. Cancer. 2014;120(24):3902–3913.
   PubMed Web of Science ®Google Scholar
• Shah AK, Cao KA, Choi E, et al. Serum glycoprotein biomarker discovery and qualification pipeline reveals novel diagnostic biomarker candidates for esophageal adenocarcinoma. Mol Cell Proteomics. 2015;14(11):3023–3039.
   PubMed Web of Science ®Google Scholar
• Mechref Y, Hussein A, Bekesova S, et al. Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. J Proteome Res. 2009;8(6):2656–2666.
   PubMed Web of Science ®Google Scholar
• Mayampurath A, Song E, Mathur A, et al. Label-free glycopeptide quantification for biomarker discovery in human sera. J Proteome Res. 2014;13(11):4821–4832.
   PubMed Web of Science ®Google Scholar
• Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 antibody research group. Cancer. 2003;97(3):682–689.
   PubMed Web of Science ®Google Scholar
• Kuge K, Murakami G, Mizobuchi S, et al. Submucosal territory of the direct lymphatic drainage system to the thoracic duct in the human esophagus. J Thorac Cardiovasc Surg. 2003;125(6):1343–1349.
   PubMed Web of Science ®Google Scholar
• Bar-Shalom R, Guralnik L, Tsalic M, et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging. 2005;32(8):918–924.
   PubMed Web of Science ®Google Scholar
• Stiles BM, Mirza F, Coppolino A, et al. Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease. Ann Thorac Surg. 2011;92(2):491–496. discussion 496-498.
   Web of Science ®Google Scholar
• Yokota T, Igaki H, Kato K, et al. Accuracy of preoperative diagnosis of lymph node metastasis for thoracic esophageal cancer patients from JCOG9907 trial. Int J Clin Oncol. 2016;21(2):283–288.
   PubMed Web of Science ®Google Scholar
• Jin H, Qiao F, Chen L, et al. Serum metabolomic signatures of lymph node metastasis of esophageal squamous cell carcinoma. J Proteome Res. 2014;13(9):4091–4103.
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Kondo T, Fujii K, et al. Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics. 2006;6(23):6300–6316.
   PubMed Web of Science ®Google Scholar
• Fu L, Qin YR, Xie D, et al. Identification of alpha-actinin 4 and 67 kDa laminin receptor as stage-specific markers in esophageal cancer via proteomic approaches. Cancer. 2007;110(12):2672–2681.
   PubMed Web of Science ®Google Scholar
• Feng JG, Liu Q, Qin X, et al. Clinicopathological pattern and Annexin A2 and Cdc42 status in patients presenting with differentiation and lymphnode metastasis of esophageal squamous cell carcinomas. Mol Biol Rep. 2012;39(2):1267–1274.
   PubMed Web of Science ®Google Scholar
• Elsner M, Rauser S, Maier S, et al. MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett’s adenocarcinoma. J Proteomics. 2012;75(15):4693–4704.
   PubMed Web of Science ®Google Scholar
• Berg D, Wolff C, Langer R, et al. Discovery of new molecular subtypes in oesophageal adenocarcinoma. PLoS One. 2011;6(9):e23985.
   PubMed Web of Science ®Google Scholar
• Xu XL, Zheng WH, Zhu SM, et al. The prognostic impact of lymph node involvement in large scale operable node-positive esophageal squamous cell carcinoma patients: a 10-year experience. PLoS One. 2015;10(7):e0133076.
   Web of Science ®Google Scholar
• Almhanna K, Shridhar R, Meredith KL. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care? Cancer Control. 2013;20(2):89–96.
   PubMed Web of Science ®Google Scholar
• Blackham AU, Yue B, Almhanna K, et al. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response. J Surg Oncol. 2015;112(6):597–602.
   PubMed Web of Science ®Google Scholar
• Hayashida Y, Honda K, Osaka Y, et al. Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. Clin Cancer Res. 2005;11(22):8042–8047.
   PubMed Web of Science ®Google Scholar
• Wen J, Zheng B, Hu Y, et al. Comparative proteomic analysis of the esophageal squamous carcinoma cell line EC109 and its multi-drug resistant subline EC109/CDDP. Int J Oncol. 2010;36(1):265–274.
   PubMed Web of Science ®Google Scholar
• De Silva N, Schulz L, Paterson A, et al. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. Br J Cancer. 2015;113(9):1305–1312.
   PubMed Web of Science ®Google Scholar
• Aichler M, Elsner M, Ludyga N, et al. Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria. J Pathol. 2013;230(4):410–419.
   PubMed Web of Science ®Google Scholar
• Shafaee A, Dastyar DZ, Islamian JP, et al. Inhibition of tumor energy pathways for targeted esophagus cancer therapy. Metabolism. 2015;64(10):1193–1198.
   PubMed Web of Science ®Google Scholar
• Kelly P, Appleyard V, Murray K, et al. Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. Br J Cancer. 2010;103(2):232–238.
   PubMed Web of Science ®Google Scholar
• Langer R, Ott K, Specht K, et al. Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response. Clin Cancer Res. 2008;263(2):280–290.
   Google Scholar
• Li C, Xia G, Jianqing Z, et al. Serum differential protein identification of Xinjiang Kazakh esophageal cancer patients based on the two-dimensional liquid-phase chromatography and LTQ MS. Mol Biol Rep. 2014;41(5):2893–2905.
   PubMed Web of Science ®Google Scholar
• Guo W, Ma X, Xue C, et al. Serum clusterin as a tumor marker and prognostic factor for patients with esophageal cancer. Dis Markers. 2014;2014:168960.
   PubMed Web of Science ®Google Scholar
• Maher SG, McDowell DT, Collins BC, et al. Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation. Ann Surg. 2011;254(5):809–816. discussion 816-807.
   PubMed Web of Science ®Google Scholar
• Leng C, Li Y, Qin J, et al. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8(+) T cells. Oncol Rep. 2016;35(2):699–708.
   PubMed Web of Science ®Google Scholar
• The Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439–4442.
   PubMed Web of Science ®Google Scholar
• Igaki H, Kato H, Tachimori Y, et al. Prognostic evaluation for squamous cell carcinomas of the lower thoracic esophagus treated with three-field lymph node dissection. Eur J Cardiothorac Surg. 2001;19(6):887–893.
   PubMed Web of Science ®Google Scholar
• Uemura N, Nakanishi Y, Kato H, et al. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. Int J Cancer. 2009;124(9):2106–2115.
   PubMed Web of Science ®Google Scholar
• Zhang K, Li L, Zhu M, et al. Comparative analysis of histone H3 and H4 post-translational modifications of esophageal squamous cell carcinoma with different invasive capabilities. J Proteomics. 2015;112:180–189.
   PubMed Web of Science ®Google Scholar
• Zheng GB, Gao CF, Wang XL, et al. Study on serum proteomic features in patients with and without recurrence or metastasis after surgical resection of esophageal carcinoma. Genet Mol Res. 2014;13(1):538–545.
   PubMed Web of Science ®Google Scholar
• Du XL, Hu H, Lin DC, et al. Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J Mol Med (Berl). 2007;85(8):863–875.
   PubMed Web of Science ®Google Scholar
• Kelly P, Paulin F, Lamont D, et al. Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br J Cancer. 2012;106(5):955–961.
   PubMed Web of Science ®Google Scholar
• Drews J. Drug discovery: a historical perspective. Science. 2000;287(5460):1960–1964.
   PubMed Web of Science ®Google Scholar
• Sleno L, Emili A. Proteomic methods for drug target discovery. Curr Opin Chem Biol. 2008;12(1):46–54.
   PubMed Web of Science ®Google Scholar
• Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg. 2001;88(3):338–356.
   PubMed Web of Science ®Google Scholar
• Kavallaris M, Marshall GM. Proteomics and disease: opportunities and challenges. Med J Aust. 2005;182(11):575–579.
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211–225.
   PubMed Web of Science ®Google Scholar
• Syed N, Barbhuiya MA, Pinto SM, et al. Phosphotyrosine profiling identifies ephrin receptor A2 as a potential therapeutic target in esophageal squamous-cell carcinoma. Proteomics. 2015;15(2–3):374–382.
   PubMed Web of Science ®Google Scholar
• Komatsu S, Imoto I, Tsuda H, et al. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis. 2009;30(7):1139–1146.
   PubMed Web of Science ®Google Scholar
• Nguyen H, Allali-Hassani A, Antonysamy S, et al. LLY-507, a cell-active, potent, and selective inhibitor of protein-lysine methyltransferase SMYD2. J Biol Chem. 2015;290(22):13641–13653.
   PubMed Web of Science ®Google Scholar
• Olsen JB, Cao XJ, Han B, et al. Quantitative profiling of the activity of protein lysine methyltransferase SMYD2 using SILAC-based proteomics. Mol Cell Proteomics. 2016;15(3):892–905.
   PubMed Web of Science ®Google Scholar
• Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist. 2001;6(Suppl 2):3–10.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li X, Li X, et al. ANXA1 silencing increases the sensitivity of cancer cells to low-concentration arsenic trioxide treatment by inhibiting ERK MAPK activation. Tumori. 2015;101(4):360–367.
   PubMed Web of Science ®Google Scholar
• Kenny PA, Bissell MJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest. 2007;117(2):337–345.
   PubMed Web of Science ®Google Scholar
• Rios-Doria J, Sabol D, Chesebrough J, et al. A monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting egfr and non-egfr-mediated pathways. Mol Cancer Ther. 2015;14(7):1637–1649.
   PubMed Web of Science ®Google Scholar
• Selga E, Noe V, Ciudad CJ. Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis. Biochem Pharmacol. 2008;75(2):414–426.
   PubMed Web of Science ®Google Scholar
• Li W, Hou G, Zhou D, et al. The roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoateinduced esophageal squamous cell carcinoma cell death. Oncotarget. 2016;7(16):21542–21555.
   Google Scholar
• Huang W, Ye M, Zhang LR, et al. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation. Mol Cancer. 2014;13:150.
   PubMed Web of Science ®Google Scholar
• Li LY, Zhang K, Jiang H, et al. Quantitative proteomics reveals the downregulation of GRB2 as a prominent node of F806-targeted cell proliferation network. J Proteomics. 2015;117:145–155.
   PubMed Web of Science ®Google Scholar
• Vona-Davis L, Vincent T, Zulfiqar S, et al. Proteomic analysis of SEG-1 human Barrett’s-associated esophageal adenocarcinoma cells treated with keyhole limpet hemocyanin. J Gastrointest Surg. 2004;8(8):1018–1023.
   PubMed Web of Science ®Google Scholar
• McFadden DW, Riggs DR, Jackson BJ, et al. Keyhole limpet hemocyanin, a novel immune stimulant with promising anticancer activity in Barrett’s esophageal adenocarcinoma. Am J Surg. 2003;186(5):552–555.
   PubMed Web of Science ®Google Scholar
• Harris JR, Markl J. Keyhole limpet hemocyanin: molecular structure of a potent marine immunoactivator. A Review Eur Urol 2000;37(Suppl 3):24–33.
   PubMed Web of Science ®Google Scholar
• Hu H, Ran Y, Zhang Y, et al. Antibody library-based tumor endothelial cells surface proteomic functional screen reveals migration-stimulating factor as an anti-angiogenic target. Mol Cell Proteomics. 2009;8(4):816–826.
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360(6):563–572.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
   PubMed Web of Science ®Google Scholar
• Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633–640.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–480.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–1338.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697.
   PubMed Web of Science ®Google Scholar
• Boland PM, Burtness B. Esophageal carcinoma: are modern targeted therapies shaking the rock? Curr Opin Oncol. 2013;25(4):417–424.
   PubMed Web of Science ®Google Scholar
• Altelaar AF, Munoz J, Heck AJR. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat Rev Genet. 2013;14(1):35–48.
   PubMed Web of Science ®Google Scholar